Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGENUS INCAGEN · Entity 5774 | Director | October 01, 2024 | October 03, 2024 |
| MiNK Therapeutics, Inc.INKT · Entity 52 | Director | September 01, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGENUS INC
Report date October 01, 2024 · Filed October 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 19,500.664 |
Reported balance
After 2024-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-10-01 · Grant · Acquired 3,423.478 · Balance 19,500.664 F1: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3: $7.49 per Deferred Stock Unit acquired on October 1, 2024. The price of each Deferred Stock Unit acquired on October 1,2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.
F2: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.
F3: $7.49 per Deferred Stock Unit acquired on October 1, 2024. The price of each Deferred Stock Unit acquired on October 1,2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.
MiNK Therapeutics, Inc.
Report date September 01, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,929 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 1,279 · Balance 23,929 F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 27,830 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 27,830 F2: Shares are held in an irrevocable trust for the benefit of Mr. Wiinberg's family. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
F2: Shares are held in an irrevocable trust for the benefit of Mr. Wiinberg's family.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 2, 2026 15:10 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,279 | $10.95 | $14,005.05 |
DisclosureSEC source: 0001193125-26-379575 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,929 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,131 | $12.38 | $14,001.78 |
DisclosureSEC source: 0001193125-26-253461 · ownership.xml · nonDerivative · entry 2 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,650 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| March 02, 2026 Filed Jun 2, 2026 20:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,285 | $10.90 | $14,006.50 |
DisclosureSEC source: 0001193125-26-253461 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,519 F3 · price: Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:24 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 5,395 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001193125-26-004786 · ownership.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,395 Underlying: Common Stock · 5,395 shares Expires 2036-01-02 F1 · derivative.exercise_date: Option vests on February 2, 2026, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:10 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,263 | $11.09 | $14,006.67 |
DisclosureSEC source: 0001193125-25-306675 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,234 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 3,225 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0001193125-25-201314 · ownership.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,225 Underlying: Common Stock · 3,225 shares Expires 2035-09-09 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:33 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,011 | $13.86 | $14,012.46 |
DisclosureSEC source: 0001193125-25-195095 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,971 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,953 | $7.17 | $14,003.01 |
DisclosureSEC source: 0000950170-25-081611 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,960 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,593 | $8.79 | $14,002.47 |
DisclosureSEC source: 0000950170-25-033525 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,007 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 15:35 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 20,476 | $0.73 | $14,947.48 |
DisclosureSEC source: 0000950170-24-132518 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,181 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 12:40 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 3,423.478 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-112007 · ownership.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500.664 Underlying: Common Stock · 3,423.478 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $7.49 per Deferred Stock Unit acquired on October 1, 2024. The price of each Deferred Stock Unit acquired on October 1,2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 12:22 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 18,295 | $0.82 | $15,001.90 |
DisclosureSEC source: 0000950170-24-103745 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,705 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| July 01, 2024 Filed Jul 1, 2024 20:05 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 2,121.119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-079585 · ownership.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,077.186 Underlying: Common Stock · 2,121.119 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $12.08 per Deferred Stock Unit acquired on July 1, 2024. The price of each Deferred Stock Unit acquired on July 1,2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 18:24 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 15,077 | $0.99 | $14,926.23 |
DisclosureSEC source: 0000950170-24-069212 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,410 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| April 01, 2024 Filed Apr 1, 2024 20:20 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 38,635.459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-039351 · ownership.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,121.341 Underlying: Common Stock · 38,635.459 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $0.66 per Deferred Stock Unit acquired on April 1, 2024. The price of each Deferred Stock Unit acquired on April 1, 2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:00 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 15,790 | $0.95 | $15,000.50 |
DisclosureSEC source: 0000950170-24-026426 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,333 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| February 05, 2024 Filed Apr 22, 2024 20:05 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option · Derivative | 5,000 | $0.00 Strike: $12.60 | $0.00 |
DisclosureSEC source: 0000950170-24-046417 · ownership.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-02-05 F1 · derivative.exercise_date: The Stock Options were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan on February 5, 2024 and will vest on February 5, 2025. The Stock Options were granted prior to the 1 for 20 reverse stock split, representing 100,000 Stock Options with an exercise price of $0.63. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 11:05 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 30,956.376 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-001478 · ownership.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,485.882 Underlying: Common Stock · 30,956.376 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $0.83 per Deferred Stock Unit acquired on January 2, 2024. The price of each Deferred Stock Unit acquired on January 2, 2024 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 14,424 | $1.04 | $15,000.96 |
DisclosureSEC source: 0000950170-23-068312 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,543 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:22 UTC | AGENUS INC AGEN · Entity 5774 | PurchaseCommon Stock | 25,000 | $0.76 | $19,000.00 |
DisclosureSEC source: 0000950170-23-064833 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,063 F1 · shares: Represents open market purchase of common stock for cash. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 21:01 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 18,001.063 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-051963 · ownership.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,529.506 Underlying: Common Stock · 18,001.063 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $1.42 per Deferred Stock Unit acquired on October 2, 2023. The price of each Deferred Stock Unit acquired on October 2, 2023 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediatlely preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. This amount also includes a downward adjustment of 75.02 Deferred Stock Units in respect of the grant dated July 3, 2023, as the average closing price used for such calculation incorrectly reflected a stock split and was increased on October 2, 2023 to $1.61 per Deferred Stock Unit. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:00 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 9,590 | $1.46 | $14,001.40 |
DisclosureSEC source: 0000950170-23-046773 · ownership.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,119 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. F2 · balance_after: In Table 1 of the Form 4 filed on June 2, 2023, the amount of securities acquired and price (column 4) and amount of securities beneficially owned following reported transaction (column 5) were erroneously reported. On June 1, 2023, 7,778 RSUs were acquired at a price of $1.80 each, resulting in a total amount of securities beneficially owned following the reported transaction of 50,529 instead of 50,706 as erroneously reported. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:30 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 16,018.322 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-017124 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,528.442 Underlying: Common Stock · 16,018.322 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $1.60 per Deferred Stock Unit acquired on July 3, 2023. The price of each Deferred Stock Unit acquired on July 3, 2023 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediat1ely preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 00:03 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0000899243-23-015837 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2033-06-14 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 23:40 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 7,955 | $1.76 | $14,000.80 |
DisclosureSEC source: 0000899243-23-014410 · doc4.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,706 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| April 03, 2023 Filed Apr 3, 2023 19:58 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 11,901.641 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-010207 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,510.12 Underlying: Common Stock · 11,901.641 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $2.153 per Deferred Stock Unit acquired on April 3, 2023. The price of each Deferred Stock Unit acquired on April 3, 2023 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediat1ely preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:23 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 6,699 | $2.09 | $14,000.91 |
DisclosureSEC source: 0000899243-23-006928 · doc4.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,751 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| January 08, 2023 Filed Jan 10, 2023 00:02 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000899243-23-001356 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-08 F1 · derivative.exercise_date: Options of Common Stock were awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan (the "2019 Plan") on January 8, 2023. Options will vest on January 8, 2024. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 16:25 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 9,893.822 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000503 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,608.479 Underlying: Common Stock · 9,893.822 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $2.590 per Deferred Stock Unit acquired on January 3, 2023. The price of each Deferred Stock Unit acquired on January 3, 2023 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 23:27 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 5,364 | $2.61 | $14,000.04 |
DisclosureSEC source: 0000899243-22-037698 · doc4.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,052 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. F2 · balance_after: Includes shares inadvertently excluded from a Form 4 filed on September 19, 2022. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 17:09 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 9,862.289 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032920 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,714.657 Underlying: Common Stock · 9,862.289 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $2.598 per Deferred Stock Unit acquired on October 3, 2022. The price of each Deferred Stock Unit acquired on October 3, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 23:06 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 10,688 | $2.62 | $28,002.56 |
DisclosureSEC source: 0000899243-22-031528 · doc4.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,688 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 19:21 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | PurchaseCommon Stock | 16,661 | $1.39 | $23,208.77 |
DisclosureSEC source: 0000899243-22-026460 · doc4.xml · nonDerivative · entry 2 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,300 F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $1.37 - $1.51. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| July 18, 2022 Filed Jul 21, 2022 19:21 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | PurchaseCommon Stock | 3,339 | $1.33 | $4,437.53 |
DisclosureSEC source: 0000899243-22-026460 · doc4.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,639 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $1.31 - $1.44. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 19:50 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 13,854.975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-025320 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,852.368 Underlying: Common Stock · 13,854.975 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $1.850 per Deferred Stock Unit acquired on July 1, 2022. The price of each Deferred Stock Unit acquired prior to July 1, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 22:26 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 9,307.809 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-013870 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,997.393 Underlying: Common Stock · 9,307.809 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $2.753 per Deferred Stock Unit acquired on April 1, 2022. The price of each Deferred Stock Unit acquired prior to April 1, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:08 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0000899243-22-010698 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 23:10 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0000899243-22-005239 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-04 F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan, as amended, and will vest on February 4, 2023. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 20:24 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 6,391.991 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-000866 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,689.584 Underlying: Common Stock · 6,391.991 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $4.009 per Deferred Stock Unit acquired on January 3, 2022. The price of each Deferred Stock Unit acquired prior to January 3, 2022 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 23:13 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 4,451.32 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-039305 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,297.593 Underlying: Common Stock · 4,451.32 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $5.757 per Deferred Stock Unit acquired on October 1, 2021. The price of each Deferred Stock Unit acquired prior to October 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 22:00 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 6,707.279 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-027312 · doc4.xml · derivative · entry 2 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,846.273 Underlying: Common Stock · 6,707.279 shares Expires not disclosed F2 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F4 · price: $3.820 per Deferred Stock Unit acquired on July 1, 2021. The price of each Deferred Stock Unit acquired prior to July 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F3 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F3 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:17 UTC | AGENUS INC AGEN · Entity 5774 | Exercise / conversionCommon Stock | 16,853 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-024971 · doc4.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 16, 2020, Mr. Wiinberg was granted 16,853 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 16, 2021, this award vested in full and Mr. Wiinberg was issued the underlying 16,853 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan. F1 · price: On June 16, 2020, Mr. Wiinberg was granted 16,853 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 16, 2021, this award vested in full and Mr. Wiinberg was issued the underlying 16,853 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan. Read SEC document |
| June 15, 2021 Filed Jul 2, 2021 22:00 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0000899243-21-027312 · doc4.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-17 F1 · derivative.exercise_date: Option was granted on January 1, 2021, subject to shareholder approval of an increase to the available pool under the Company's 2019 Equity Incentive Plan ("2019 Plan"), which was obtained at the Company's annual shareholder meeting on June 15, 2021. Option awarded in accordance with the 2019 Plan. Option vests in full on December 17, 2022. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:22 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 6,959.905 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001745285-21-000015 · primary_doc.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,098.9 Underlying: Common Stock · 6,959.905 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $3.682 per Deferred Stock Unit acquired on April 1, 2021. The price of each Deferred Stock Unit acquired prior to April 1, 2021 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:27 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 5,896.535 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001745285-21-000004 · primary_doc.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,179.09 Underlying: Common Stock · 5,896.535 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $3.780 per Deferred Stock Unit acquired on January 4, 2021. The price of each Deferred Stock Unit acquire prior to January 4, 2021 is the average of the closing price for the Company's Common Stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's Common Stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's Common Stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 19:44 UTC | AGENUS INC AGEN · Entity 5774 | GrantStock Option (Right to buy) · Derivative | 100,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001745285-20-000051 · primary_doc.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-17 F1 · derivative.exercise_date: Stock Option awarded in accordance with the Agenus Inc. 2019 Equity Incentive Plan. The Stock Option vests in full on December 17, 2021 (provided Mr. Wiinberg continues to serve on the board on such date). Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 19:00 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 6,464.583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001745285-20-000035 · primary_doc.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,282.555 Underlying: Common Stock · 6,464.583 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $3.964 per Deferred Stock Unit acquired on October 1, 2020. The price of each Deferred Stock Unit acquired prior to October 1, 2020 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquire pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to be a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to be a director of the Company. Read SEC document |
| July 01, 2020 Filed Jul 1, 2020 22:50 UTC | AGENUS INC AGEN · Entity 5774 | GrantDeferred Stock Units · Derivative | 8,398.143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001745285-20-000024 · primary_doc.xml · derivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,817.972 Underlying: Common Stock · 8,398.143 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis. F3 · price: $3.051 per Deferred Stock Unit acquired on July 1, 2020. The price of each Deferred Stock Unit acquired prior to July 1, 2020 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan. F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 20:33 UTC | AGENUS INC AGEN · Entity 5774 | Exercise / conversionRestricted Stock Unit · Derivative | 20,338 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001745285-20-000020 · primary_doc.xml · derivative · entry 2 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,338 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan. F1 · shares: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan. F1 · price: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan. F1 · derivative.exercise_date: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan. F1 · derivative.expiration_date: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 20:33 UTC | AGENUS INC AGEN · Entity 5774 | Exercise / conversionCommon Stock | 20,338 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001745285-20-000020 · primary_doc.xml · nonDerivative · entry 1 WIINBERG ULF · CIK 0001187314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan. F1 · price: On June 19, 2019, Mr. Wiinberg was granted 20,338 Restricted Stock Units as part of his annual compensation for service on the Executive Committee of the Agenus Inc. Board of Directors. On June 19, 2020, this award vested in full and Mr. Wiinberg was issued the underlying 20,338 shares of common stock, all in accordance with the Agenus Inc. 2019 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.